Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity

被引:286
作者
Rybak, MJ
Abate, BJ
Kang, SL
Ruffing, MJ
Lerner, SA
Drusano, GL
机构
[1] Detroit Receiving Hosp & Univ Hlth Ctr, Dept Pharm Serv, Antiinfect Res Lab, Coll Pharm & Allied Hlth Profess, Detroit, MI 48201 USA
[2] Wayne State Univ, Sch Med, Dept Internal Med, Div Infect Dis, Detroit, MI 48201 USA
[3] Albany Med Coll, Div Clin Pharmacol, Dept Med, Albany, NY 12208 USA
[4] Albany Med Coll, Div Clin Pharmacol, Dept Pharmacol, Albany, NY 12208 USA
关键词
D O I
10.1128/AAC.43.7.1549
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The nephrotoxicity and ototoxicity associated with once-daily versus twice-daily administration of aminoglycosides was assessed in patients with suspected or proven gram-negative bacterial infections in a randomized, double-blind clinical trial, Patients who received therapy for greater than or equal to 72 h were evaluated for toxicity. Patients also received concomitant antibiotics as deemed necessary for treatment of their infection. Plasma aminoglycoside concentrations, prospective aminoglycoside dosage adjustment, and serial audiologic and renal status evaluations were performed. The probability of occurrence of a nephrotoxic event and its relationship to doses and daily aminoglycoside exposure served as the main outcome measurement. One hundred twenty-three patients were enrolled in the study, with 83 patients receiving therapy for at least 72 h, For 74 patients plasma aminoglycoside concentrations were available for analysis, and the patients formed the group evaluable for toxicity. The primary infectious diagnosis for the patients who were enrolled in the study were bacteremia or sepsis, respiratory infections, skin and soft tissue infections, or urosepsis or pyelonephritis. Of the 74 patients evaluable for toxicity, 39 received doses twice daily and 35 received doses once daily and a placebo 12 h later. Nephrotoxicity occurred in 6 of 39 (15.4%) patients who received aminoglycosides twice daily and 0 of 35 patients who received aminoglycosides once daily, The schedule of aminoglycoside administration, concomitant use of vancomycin, and daily area under the plasma concentration-time curve (AUC) for the aminoglycosides were found to be significant predictors of nephrotoxicity by multivariate logistic regression analysis (P less than or equal to 0.001). The time to a nephrotoxic event was significantly influenced by vancomycin use and the schedule of administration, as assessed by Cox proportional hazards modeling (P less than or equal to 0.002). The results of the multivariate logistic regression analysis and the Cox proportional hazards modeling demonstrate that both the probability of occurrence and the time to occurrence of aminoglycoside nephrotoxicity are influenced by the schedule on which the aminoglycoside is administered as well as by the concomitant use of vancomycin, Furthermore, this risk of occurrence is modulated by the daily AUC for aminoglycoside exposure. These data suggest that once-daily administration of aminoglycosides has a predictably lower probability of causing nephrotoxicity than twice-daily administration.
引用
收藏
页码:1549 / 1555
页数:7
相关论文
共 41 条
[11]   WHAT IS THE COST OF NEPHROTOXICITY ASSOCIATED WITH AMINOGLYCOSIDES [J].
EISENBERG, JM ;
KOFFER, H ;
GLICK, HA ;
CONNELL, ML ;
LOSS, LE ;
TALBOT, GH ;
SHUSTERMAN, NH ;
STROM, BL .
ANNALS OF INTERNAL MEDICINE, 1987, 107 (06) :900-909
[12]   COMPARATIVE KINETICS AND EFFICACY OF AMIKACIN ADMINISTERED ONCE OR TWICE DAILY IN THE TREATMENT OF SYSTEMIC GRAM-NEGATIVE INFECTIONS [J].
GIAMARELLOU, H ;
YIALLOUROS, K ;
PETRIKKOS, G ;
MOSCHOVAKIS, E ;
VAVOURAKI, E ;
VOUTSINAS, D ;
SFIKAKIS, P .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 27 :73-79
[13]   ONCE-DAILY AMINOGLYCOSIDE THERAPY [J].
GILBERT, DN .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (03) :399-405
[15]   A MULTICENTRIC STUDY OF NETILMICIN ONCE DAILY VERSUS THRICE DAILY IN PATIENTS WITH APPENDICITIS AND OTHER INTRA-ABDOMINAL INFECTIONS [J].
HOLLENDER, LF ;
BAHNINI, J ;
DEMANZINI, N ;
LAU, WY ;
FAN, ST ;
HERMANSYUR, K ;
BENNY, P ;
HUSNI, AN ;
SUTJIPTO ;
LORBER, RR .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1989, 23 (05) :773-783
[16]   SINGLE, LARGE, DAILY DOSING VERSUS INTERMITTENT DOSING OF TOBRAMYCIN FOR TREATING EXPERIMENTAL PSEUDOMONAS PNEUMONIA [J].
KAPUSNIK, JE ;
HACKBARTH, CJ ;
CHAMBERS, HF ;
CARPENTER, T ;
SANDE, MA .
JOURNAL OF INFECTIOUS DISEASES, 1988, 158 (01) :7-12
[17]   APACHE-II - A SEVERITY OF DISEASE CLASSIFICATION-SYSTEM [J].
KNAUS, WA ;
DRAPER, EA ;
WAGNER, DP ;
ZIMMERMAN, JE .
CRITICAL CARE MEDICINE, 1985, 13 (10) :818-829
[18]   ONCE-DAILY AMINOGLYCOSIDE ADMINISTRATION - NEW STRATEGIES FOR AN OLD DRUG [J].
KOVARIK, JM ;
HOEPELMAN, IM ;
VERHOEF, J .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1989, 8 (09) :761-769
[19]   COMPARATIVE-STUDY OF OTOTOXICITY AND NEPHROTOXICITY IN PATIENTS RANDOMLY ASSIGNED TO TREATMENT WITH AMIKACIN OR GENTAMICIN [J].
LERNER, SA ;
SCHMITT, BA ;
SELIGSOHN, R ;
MATZ, GJ .
AMERICAN JOURNAL OF MEDICINE, 1986, 80 (6B) :98-104
[20]   EFFICACY AND SAFETY OF AMIKACIN IN SYSTEMIC INFECTIONS WHEN GIVEN AS A SINGLE DAILY DOSE OR IN 2 DIVIDED DOSES [J].
MALLER, R ;
AHRNE, H ;
EILARD, T ;
ERIKSSON, I ;
LAUSEN, I .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 27 :121-128